OaxaCannabis

12/11/2025

Los cannabinoides en la investigación preclínica de la sepsis: una revisión exhaustiva.
Los cannabinoides son dianas terapéuticas prometedoras en el tratamiento de la sepsis, ya que mejoran la supervivencia y reducen la inflamación y las lesiones orgánicas. Sin embargo, se notificaron efectos adversos nocivos, cuyos mecanismos moleculares subyacentes aún se desconocen, y es necesario seguir investigando para evaluar sus beneficios y su futuro uso en la investigación clínica.
---
Cannabinoids in preclinical research of sepsis: a scoping review.
Cannabinoids are promising therapeutic targets in the treatment of sepsis, as they improved survival, and reduced inflammation and organ injury. However, deleterious adverse effects were reported, with the underlying molecular mechanisms still unknown, and further research is needed to evaluate their benefits and future use in clinical research.

https://link.springer.com/article/10.1007/s00011-025-02090-9

Foto por formulario PxHere.

07/11/2025

https://neurosciencenews.com/nano-tech-cbd-pain-29910/

A new study shows that CBD delivered through a nano-micelle system can cross the blood–brain barrier and produce rapid neuropathic pain relief.

28/10/2025

https://www.cannabistrades.org/stories/polyploid-and-triploid-cannabis-what-s-the-difference-and-why-does-it-matter

Every living thing, from humans to plants, has chromosomes, tiny packages of DNA that carry genetic information. The number of chromosome sets a plant has is described by the term ploidy.

02/10/2025

Psilocybin Rewire Brain Circuits Tied to Pain and Mood

Researchers have shown that psilocybin, the psychedelic compound in mushrooms, can relieve chronic pain and depression-like symptoms by targeting brain circuits rather than the site of injury.

In mice, a single dose eased suffering for nearly two weeks by modulating serotonin activity in the anterior cingulate cortex.

Unlike opioids, psilocybin worked like a “dimmer switch,” finely tuning signals rather than shutting them off completely.

The findings point to a promising new class of non-addictive treatments for chronic pain and mood disorders.

23/09/2025

https://medicalxpress.com/news/2025-09-body-endocannabinoid-receptor-result-neuropsychiatric.html

Endocannabinoids are similar to the cannabinoids present in cannabis, but they are found naturally in the body. Endocannabinoids—and cannabinoids—work through a signaling system that supports neurodevelopment, but whether manipulating this system prenatally has long-lasting effects remains uncle...

17/09/2025

https://www.goodnewsnetwork.org/depression-patients-treated-with-psychedelic-mushrooms-5-years-ago-are-still-symptom-free/

The study involved participants from a trial published in 2021 that found psilocybin—the primary psychedelic substance produced by mushrooms.

12/09/2025

https://medicalxpress.com/news/2025-09-distinct-psilocybin-oscillations-rat-medial.html

Psychedelics, a class of psychoactive drugs that typically induce peculiar mental states and hallucinations, are still prohibited for recreational use in most countries worldwide. In recent years, some neuroscientists and medical researchers have been exploring the potential therapeutic effects of t...

03/09/2025

Un estudio reveló que la ansiedad, la depresión y el dolor crónico eran las indicaciones más comunes del cannabis medicinal, aunque la situación legal influyó en el consumo y en las afecciones tratadas.
Los participantes declararon diversos métodos de consumo, siendo fumar el más común, aunque también se asoció con el mayor índice de efectos secundarios.
En general, el 32,3% de los participantes calificaron el cannabis de muy eficaz para su afección principal.
---
A study revealed that anxiety, depression, and chronic pain were the most common indications for medical cannabis, although legal status influenced use and conditions treated.
Participants reported a variety of methods of use, with smoking being the most common, although it was also associated with the highest rate of side effects.
Overall, 32.3% of participants rated cannabis as very effective for their primary condition.

https://www.sciencedirect.com/science/article/pii/S2773065425000847

Foto de Kindel Media en Pexels.

27/08/2025

Registro de Cannabis Medicinal del Reino Unido: Un análisis clínico de pacientes con trastorno por consumo de sustancias.
Hubo una mejora asociada en la calidad de vida relacionada con la salud informada por el paciente y una reducción en los opioides prescritos en individuos con trastorno por uso de sustancias tratados con productos medicinales a base de Cannabis. Éstos fueron bien tolerados por la mayoría de los individuos en este análisis de 6 meses.
----
UK Medical Cannabis Registry: A Clinical Analysis of Patients with Substance Use Disorder.
There was an associated improvement in health-related quality of life patient-reported and reduction in prescribed opioids in individuals with substance use disorder treated with Cannabis-based medicinal products. Those were well tolerated by most individuals in this 6-month analysis.

https://karger.com/ear/article/doi/10.1159/000547696/931298/UK-Medical-Cannabis-Registry-A-Clinical-Analysis

Foto de MART PRODUCTION en Pexels.

27/08/2025

NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we’re helpi...

27/08/2025

https://www.forbes.com/sites/andrewdeangelo/2025/08/19/the-science-behind-the-fight-over-7-oh/

The FDA requested the DEA ban the compound 7-OH citing increased risk of abuse. 7-OH is an alkaloid in the kratom plant. It's used for pain and harm reduction.